Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome

NCT06872125 is registered in ClinicalTrials.gov with Stoke Therapeutics, Inc as lead sponsor.

NCT NCT06872125
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06872125 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
EMPEROR: A Multicenter, Randomized, Double-blind, Sham-controlled, Parallel Group, Phase 3 Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen (STK-001) in Patients With Dravet Syndrome
Lead sponsor
Stoke Therapeutics, Inc
Phase
Phase 3
Overall status
Recruiting
Start date
June 4, 2025
Completion date
October 31, 2028
Enrollment
170 (estimated)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

dravet syndrome